global
vaccin
action
plan
gvap
framework
endors
world
health
assembl
improv
health
extend
full
benefit
immun
peopl
regardless
born
live
march
world
health
organ
nation
institut
allergi
infecti
diseas
niaid
part
us
nation
institut
health
nih
bill
melinda
gate
foundat
bmgf
conven
lead
scientist
vaccin
develop
public
health
offici
around
world
third
global
vaccin
immun
research
forum
gvirf
held
bangkok
thailand
previou
meet
gvirf
track
progress
gvap
research
develop
agenda
identifi
opportun
challeng
meet
gvap
goal
promot
partnership
vaccin
research
progress
gvap
research
develop
agenda
strong
mani
import
gvap
target
met
particular
global
coverag
basic
vaccin
improv
littl
sinc
leav
estim
million
children
unreach
incomplet
vaccin
respons
gap
gvirf
featur
two
overarch
theme
innov
equiti
endtoend
integr
report
summar
forum
discuss
present
materi
gvirf
found
http
present
gvirf
innov
widespread
along
immun
valu
chain
progress
made
advanc
prioriti
vaccin
enabl
technolog
develop
approach
improv
immun
coverag
impact
build
capac
innov
particularli
middleand
lowincom
countri
two
pivot
hiv
vaccin
efficaci
trial
underway
expect
provid
efficaci
signal
around
first
followon
clinic
trial
thailand
demonstr
safeti
modest
efficaci
hiv
prevent
vaccin
trial
test
alvacc
prime
alvacc
bival
envelop
env
boost
clinicaltrialsgov
half
target
popul
adult
enrol
south
africa
februari
second
trial
use
vector
prime
env
protein
boost
aim
global
crossclad
protect
studi
enrol
women
six
african
countri
base
recent
recommend
highrisk
popul
particip
offer
stateoftheart
hiv
risk
reduct
method
preexposur
prophylaxi
addit
studi
evalu
differ
adjuv
prime
regimen
run
parallel
inform
clinic
develop
hiv
immun
strategi
pose
deliveri
challeng
target
highrisk
adult
popul
routin
vaccin
requir
complex
vaccin
regimen
gvirf
particip
note
implement
research
crucial
effici
protect
popul
pipelin
tb
vaccin
includ
subunit
protein
viral
vector
wholecel
inactivatedand
liveattenu
candid
recent
studi
adolesc
test
two
approach
vaccin
recombin
fusion
protein
adjuv
bacil
calmetteguerin
bcg
revaccin
earli
analysi
show
welltoler
neither
vaccin
show
statist
signific
prevent
initi
infect
bcg
revaccin
demonstr
statist
signific
reduct
sustain
infect
gave
statist
signific
reduct
sustain
infect
result
inform
tb
vaccin
product
develop
may
support
identif
correl
protect
studi
addit
vaccin
candid
expect
gener
efficaci
data
sinc
meet
result
publish
show
recombin
vaccin
significantli
protect
tuberculosi
diseas
prioriti
tb
vaccin
research
includ
develop
control
human
infect
model
understand
altern
clinic
endpoint
prevent
infect
diseas
recurr
reinfect
use
inform
diseas
control
strategi
receiv
posit
scientif
opinion
european
medicin
agenc
ema
first
malaria
vaccin
rt
gsk
mosquirix
deploy
pilot
studi
ghana
kenya
malawi
begin
studi
assess
oper
feasibl
safeti
impact
rt
yield
result
inform
recommend
use
fund
decis
rt
predict
substanti
health
impact
gvirf
particip
observ
remain
need
malaria
vaccin
high
durabl
efficaci
effect
plasmodium
falciparum
plasmodium
vivax
interrupt
transmiss
suitabl
use
older
children
adult
includ
pregnant
women
mani
gap
address
divers
pipelin
includ
monoclon
antibodi
well
vaccin
target
parasit
preerythrocyt
stage
asexu
blood
stage
sexual
stage
crossprotect
univers
influenza
vaccin
would
transform
season
influenza
prevent
pandem
respons
annual
revaccin
would
longer
necessari
dose
could
stockpil
rapid
deploy
event
pandem
multipl
candid
target
conserv
region
hemagglutinin
protein
clinic
develop
facilit
develop
univers
influenza
vaccin
niaid
establish
definit
univers
influenza
vaccin
describ
strateg
plan
research
agenda
vaccin
develop
provid
technic
assist
influenza
vaccin
research
definit
univers
influenza
vaccin
would
least
efficaci
symptomat
influenza
infect
protect
group
ii
influenza
virus
least
one
year
suitabl
age
group
new
vitro
technolog
human
immunolog
research
vaccin
evalu
describ
gvirf
includ
mass
cytometri
cytof
allow
simultan
analysi
marker
singlecel
resolut
singlecel
tcell
receptor
tcr
sequenc
combin
group
lymphocyt
interact
paratop
hotspot
gliph
identifi
converg
group
tcr
discov
ligand
antigen
futur
vaccin
design
mimic
system
use
human
peripher
blood
mononuclear
cell
simul
innat
adapt
immun
respons
vitro
model
human
immun
system
intend
provid
clinic
relev
inform
much
earlier
develop
process
mimic
use
identifi
malaria
peptid
strong
tcell
respons
profil
consider
novel
malaria
vaccin
expect
immunolog
tool
contribut
better
understand
protect
immun
acceler
develop
approv
new
vaccin
among
mani
avail
vaccin
vector
develop
two
highlight
confer
cytomegaloviru
cmv
base
vector
plasmid
launch
liveattenu
vaccin
pllav
cmvbase
vector
vaccin
elicit
maintain
high
frequenc
effector
memori
tcell
respons
mucos
site
lymphoid
tissu
parenchym
organ
nonhuman
primat
effici
reinfect
persist
despit
robust
anticmv
immun
cmvbase
vector
use
repeatedli
induc
respons
success
antigen
highli
attenu
human
cmvvector
hiv
vaccin
cgmp
manufactur
slate
clinic
test
pllav
e
coliproduc
dna
vaccin
upon
administr
replic
mammalian
cell
assembl
viru
particl
infect
amplifi
surround
cell
function
liveattenu
yellow
fever
vaccin
demonstr
proofofconcept
studi
small
anim
nonhuman
primat
approach
potenti
serv
platform
technolog
target
includ
pathogen
epidem
potenti
lassa
fever
viru
control
human
infect
model
chim
acceler
vaccin
develop
diseas
infecti
agent
clinic
cours
appropri
understood
chim
safe
give
consist
rate
infect
describ
gvirf
chim
use
studi
pathogenesi
assess
correl
protect
provid
efficaci
data
cholera
typhoid
vaccin
licensur
downselect
among
enterotoxogen
e
coli
etec
vaccin
candid
develop
chim
diseas
challeng
due
complex
infecti
agent
hostpathogen
interact
variabl
infect
rate
complex
diseas
profil
particip
call
greater
standard
chim
guidelin
chim
studi
use
support
licensur
focu
endus
popul
exampl
chim
site
endem
area
applic
advanc
immunolog
chim
identifi
correl
protect
equin
human
antibodi
use
centuri
provid
passiv
immun
monoclon
antibodi
mab
offer
potenti
safer
effect
passiv
immun
gvirf
present
describ
progress
develop
mab
prophylaxi
treatment
multipl
diseas
rabi
first
prophylact
mab
serum
institut
india
rabishield
approv
india
facilit
broader
licensur
use
rabi
mab
us
food
drug
administr
fda
clarifi
regulatori
consider
evalu
polici
recommend
hiv
antibodi
mediat
prevent
studi
test
broadli
neutral
mab
eg
studi
expect
provid
result
timefram
respiratori
syncyti
viru
rsv
prophylact
mab
requir
monthli
administr
astrazeneca
palivizumab
market
decad
phase
studi
extend
halflif
rsv
prefus
fprotein
mab
healthi
preterm
infant
near
complet
result
expect
success
product
would
afford
exist
mab
requir
singl
administr
influenza
broadli
protect
mab
applic
treatment
sever
influenza
prevent
infect
vaccin
feasibl
earli
pandem
vaccin
antigen
discoveri
influenza
mab
pipelin
includ
candid
confirm
effect
viru
shed
administ
postchalleng
chim
impact
lowincom
countri
mab
must
afford
avail
suffici
suppli
antibodi
engin
use
improv
potenc
pharmacokinet
product
meet
challeng
target
product
profil
comput
analysi
identifi
mab
predict
improv
thermost
characterist
support
develop
altern
host
novel
express
system
reduc
product
cost
gvirf
particip
comment
robust
regulatori
guidanc
prequalif
pathway
essenti
facilit
licensur
use
impact
mab
respons
west
african
ebola
outbreak
r
blueprint
action
prevent
epidem
launch
may
acceler
research
develop
vaccin
treatment
diagnost
epidem
prevent
respons
diseas
priorit
blueprint
crimeancongo
haemorrhag
fever
ebola
viru
diseas
marburg
viru
diseas
lassa
fever
middl
east
respiratori
syndrom
sever
acut
respiratori
syndrom
nipah
henipavir
diseas
rift
valley
fever
zika
diseas
x
refer
emerg
pathogen
yet
identifi
may
caus
epidem
human
diseas
futur
blueprint
roadmap
target
product
profil
develop
current
version
document
avail
websit
norm
standard
tailor
epidem
context
formul
includ
approach
regulatori
pathway
ethic
issu
clinic
trial
design
data
sampl
share
capac
build
roadmap
guidelin
reduc
time
start
outbreak
test
candid
intervent
highlight
keynot
speaker
dr
alejandro
cravioto
implement
research
deliveri
innov
nation
immun
program
strengthen
strong
overal
health
system
essenti
ensur
children
receiv
vaccin
need
address
inequ
access
vaccin
requir
innov
find
children
miss
understand
address
reason
unor
undervaccin
make
product
robust
easier
deliv
ad
promis
challeng
immun
new
target
popul
adolesc
new
vaccin
complex
regimen
difficult
deliv
especi
lowresourc
set
implement
research
requir
inform
polici
decis
guid
deliveri
demonstr
malaria
vaccin
pilot
studi
studi
larg
expens
conduct
new
paradigm
need
implement
research
integr
part
vaccin
develop
new
paradigm
crucial
realiz
full
benefit
immun
india
mission
indradhanush
mi
launch
improv
immun
coverag
children
pregnant
women
ultim
reach
district
across
state
union
territori
strengthen
immun
multidimension
approach
combin
capac
build
detail
plan
measur
account
use
inform
technolog
find
reach
unreach
polit
support
highest
level
mi
help
increas
proport
fulli
immun
infant
india
successor
intensifi
mission
indradhanush
aim
fulli
immun
indian
infant
innov
program
use
social
media
target
underserv
popul
address
vaccin
hesit
suzhou
china
new
citizen
transact
center
regist
migratori
children
public
servic
account
wechat
social
media
app
use
schedul
vaccin
appoint
send
remind
dissemin
inform
ukrain
group
chat
health
profession
organ
parent
commun
address
concern
vaccin
gvirf
particip
observ
technolog
social
media
enorm
potenti
improv
social
mobil
vaccin
accept
human
papillomaviru
hpv
vaccin
experi
shown
countrydriven
oper
research
implement
scienc
need
achiev
high
coverag
noninf
popul
countri
conduct
hpv
demonstr
project
implement
schoolbas
program
target
adolesc
girl
mani
also
provid
vaccin
health
facil
reach
girl
formal
school
system
gvirf
particip
note
schoolbas
program
could
provid
platform
deliveri
addit
servic
adolesc
must
complement
program
target
million
children
school
facilit
high
coverag
social
mobil
need
increas
awar
reduc
vaccin
hesit
immun
pregnanc
wellestablish
approach
prevent
diseas
mother
infant
recommend
influenza
tetanu
vaccin
pregnanc
addit
vaccin
recommend
specif
situat
diseas
outbreak
vaccin
also
develop
matern
immun
protect
infant
rsv
group
b
streptococcu
gb
program
immun
pregnant
women
tetanu
shown
multipl
deliveri
approach
may
need
reach
vulner
popul
issu
servic
qualiti
vaccin
hesit
must
address
gvirf
particip
comment
oper
research
need
effici
deliv
new
matern
immun
vaccin
introduc
new
vaccin
pregnant
women
creat
opportun
strengthen
antenat
care
introduct
must
support
robust
monitor
poor
pregnanc
outcom
advers
event
follow
immun
whether
relat
unrel
vaccin
risk
fals
attribut
poor
outcom
new
product
must
address
includ
proactiv
educ
commun
frequenc
poor
pregnanc
outcom
absenc
vaccin
capac
vaccin
evalu
crucial
particularli
public
health
emerg
regulatori
decisionmak
lowand
middleincom
countri
strengthen
regulatori
train
exercis
joint
evalu
initi
develop
countri
vaccin
regul
network
african
vaccin
regulatori
forum
challeng
remain
especi
human
efficaci
studi
ethic
feasibl
ema
us
fda
implement
altern
regulatori
pathway
facilit
evalu
licensur
use
new
vaccin
includ
emerg
infecti
diseas
nation
regulatori
author
nra
similar
necessarili
equival
program
streamlin
regulatori
process
intern
council
harmonis
engag
regulatori
harmon
converg
align
requir
technic
guidanc
procedur
gvirf
particip
emphas
import
relianc
mechan
wherebi
highcapac
nra
provid
assist
nra
countri
develop
guidanc
countri
implement
mechan
developingcountri
vaccin
manufactur
dcvm
suppli
vaccin
world
birth
cohort
annual
whoprequalifi
vaccin
manufactur
dcvm
yet
lowand
lowermiddleincom
countri
serv
togeth
account
global
vaccin
revenu
meanwhil
dcvm
intens
pressur
suppli
qualiti
product
lowest
possibl
price
exampl
unicef
procur
dtphepbhib
vaccin
less
per
dose
price
may
unsustain
manufactur
gvirf
particip
emphas
access
afford
vaccin
requir
price
sustain
manufactur
long
term
matur
dcvm
gone
beyond
reli
partner
technolog
transfer
support
inhous
develop
new
product
ensur
sustain
commerci
viabil
requir
robust
busi
case
product
busi
risk
includ
long
develop
timelin
regulatori
complex
extend
time
market
lack
demand
predict
lead
poor
capac
util
high
fix
cost
divers
procur
mechan
pressur
unsustain
low
price
region
market
difficult
achiev
economi
scale
patent
restrict
also
creat
barrier
dcvm
particip
observ
nation
govern
region
bodi
contribut
strengthen
nation
regulatori
author
provid
incent
direct
invest
foster
support
busi
environ
improv
intellectu
properti
landscap
build
highli
skill
workforc
keynot
speaker
dr
maharaj
kishan
bhan
describ
develop
countri
achiev
independ
biomanufactur
also
signific
export
stream
india
vaccinolog
effort
help
transform
biotechnolog
research
landscap
ten
year
ago
indian
vaccin
compani
struggl
basic
today
vaccin
manufactur
develop
launch
new
combin
vaccin
new
vaccin
diseas
japanes
enceph
mening
rotaviru
influenza
typhoid
cholera
manag
robust
product
develop
pipelin
india
vaccin
sector
aspir
contribut
significantli
scientif
knowledg
drive
innov
increas
impact
scienc
biotechnolog
parallel
institut
framework
design
foster
innov
support
translat
take
shape
emphasi
evidencebas
decis
make
empow
industri
contribut
economi
public
good
evolut
key
lesson
innov
high
qualiti
requir
global
cooper
well
fund
indou
vaccin
action
program
collabor
support
spectrum
activ
relat
vaccin
immun
show
power
cooper
program
help
develop
india
first
indigen
rotaviru
vaccin
support
new
vaccin
dengu
malaria
tb
diseas
collabor
emerg
opportun
learn
global
leader
vaccinolog
global
mindset
global
ambit
india
vaccin
industri
second
overarch
theme
gvirf
reflect
ongo
shift
silo
approach
integr
endtoend
perspect
consid
new
vaccin
deploy
part
comprehens
diseas
control
strategi
three
decad
world
health
assembl
resolut
erad
polio
diseas
remain
endem
three
countri
pakistan
afghanistan
nigeria
vaccin
mainstay
polio
erad
current
vaccin
limit
well
benefit
oral
polioviru
vaccin
opv
contain
liveattenu
virus
deriv
three
type
wild
polioviru
wpv
vaccin
give
individu
protect
paralyt
polio
block
transmiss
viru
rare
attenu
vaccin
strain
give
rise
circul
vaccinederiv
poliovirus
cvdpv
resembl
wpv
transmiss
virul
three
vaccin
strain
type
vaccin
strain
lead
caus
cvdpv
contrast
inactiv
polioviru
vaccin
ipv
confer
individu
protect
three
type
polioviru
block
polioviru
transmiss
result
countri
high
risk
polio
import
transmiss
opv
remain
primari
tool
polio
erad
properti
opv
ipv
add
complex
polio
erad
illustr
opv
switch
type
wpv
declar
erad
creat
opportun
halt
use
type
opv
strain
accordingli
april
may
countri
repres
approxim
million
annual
birth
switch
use
trival
opv
topv
bival
opv
without
type
vaccin
reduc
risk
type
cvdpv
emerg
popul
immun
began
declin
switch
made
synchroni
minim
time
includ
destruct
topv
stock
addit
inactiv
polio
vaccin
ipv
introduc
routin
immun
schedul
limit
risk
immun
gap
type
polioviru
sinc
switch
number
countri
detect
type
cvdpv
decreas
howev
still
caus
outbreak
particularli
area
low
vaccin
coverag
mani
strain
aros
switch
like
origin
monoval
type
opv
use
contain
outbreak
other
may
arisen
inadvert
use
topv
facilit
polio
erad
effort
underway
develop
improv
ipv
confer
mucos
immun
safer
oral
vaccin
use
genet
stabl
approach
noninfecti
viruslik
particl
success
new
product
address
persist
risk
vaccinederiv
polioviru
pneumococc
conjug
vaccin
pcv
introduc
countri
avert
estim
pneumococc
death
global
limit
serotyp
replac
observ
nonvaccinetyp
invas
pneumococc
diseas
ipd
increas
pcv
introduct
increas
small
compar
impact
vaccinetyp
diseas
overal
pcv
give
sustain
net
declin
ipd
gvirf
particip
describ
two
futur
direct
pneumococc
vaccin
first
optim
number
dose
schedul
improv
sustain
without
sacrif
impact
current
data
suggest
twodos
primari
seri
follow
booster
dose
may
provid
better
herd
protect
whorecommend
threedos
primari
seri
singl
primari
immun
follow
booster
dose
may
suffici
maintain
herd
immun
addit
studi
underway
evalu
altern
dose
regimen
second
target
new
vaccin
expand
protect
prevent
serotyp
replac
candid
develop
includ
higher
valenc
pcv
address
addit
serotyp
protein
wholecel
vaccin
could
broad
efficaci
serotyp
rotaviru
vaccin
use
half
countri
seven
licens
rotaviru
vaccin
four
receiv
prequalif
efficaci
among
children
five
year
age
invers
relat
underf
mortal
rate
vaccin
reduc
rotaviru
acut
gastroenter
hospit
emerg
depart
visit
countri
low
child
mortal
countri
high
child
mortal
signific
reduct
hospit
also
observ
nonvaccin
children
set
provid
evid
herd
protect
gvirf
particip
emphas
import
understand
gut
environ
influenc
respons
rotaviru
vaccin
improv
vaccin
perform
nonrepl
inject
vaccin
may
better
perform
set
develop
altern
approach
improv
efficaci
countri
high
child
mortal
exist
system
tool
inadequ
address
threat
influenza
pandem
coordin
global
effort
underway
improv
pandem
prepared
pandem
influenza
risk
manag
guidelin
recommend
countri
implement
riskbas
integr
approach
pandem
influenza
prepared
half
countri
howev
publicli
avail
nation
prepared
plan
mani
exist
plan
outdat
incomplet
event
pandem
multipl
challeng
effect
respons
includ
signific
delay
start
pandem
first
avail
vaccin
limit
global
vaccin
manufactur
capac
address
delay
vaccin
avail
univers
influenza
vaccin
develop
describ
address
capac
shortag
ensur
nation
region
suppli
sever
develop
countri
partner
build
domest
influenza
vaccin
manufactur
capac
six
achiev
approv
conduct
clinic
trial
pandem
influenza
vaccin
notabl
thailand
develop
manufactur
influenza
vaccin
build
influenza
vaccinemanufactur
facil
capac
produc
million
dose
adjuv
monoval
pandem
vaccin
year
global
observatori
health
research
develop
vaccin
pipelin
tracker
show
substanti
vaccin
develop
pipelin
vaccin
account
half
candid
track
global
observatori
estim
novel
vaccin
could
licens
pipelin
report
summar
vaccin
research
develop
avail
websit
gvirf
particip
observ
given
limit
resourc
compet
prioriti
altern
intervent
treatment
prevent
valu
proposit
new
vaccin
increasingli
import
decis
tool
full
public
health
valu
proposit
fphvp
intend
facilit
evidencebas
decis
vaccin
invest
help
funder
manufactur
countri
set
prioriti
describ
role
new
vaccin
context
overal
diseasecontrol
strategi
provid
endtoend
review
evid
present
comprehens
analysi
valu
vaccin
fphvp
go
beyond
customari
perspect
direct
individu
health
benefit
attempt
captur
full
econom
societ
benefit
vaccin
prevent
lag
licensur
uptak
identifi
evid
gap
must
address
oper
research
need
product
complex
deliveri
requir
fphvp
develop
vaccin
target
gb
etec
herp
simplex
viru
addit
fphvp
consid
present
gvirf
rsv
research
develop
pipelin
robust
three
approach
pursu
protect
neonat
infant
matern
immun
pregnanc
infant
immun
shortli
birth
passiv
immun
mab
interim
efficaci
result
advanc
matern
vaccin
candid
report
gvirf
confer
medic
signific
rsv
lower
respiratori
tract
infect
confid
interv
infant
immun
strategi
earlier
phase
studi
improv
mab
passiv
immun
develop
describ
product
approach
licensur
polici
consider
minimum
accept
efficaci
effect
season
impact
concurr
condit
hiv
infect
effect
matern
immun
deliveri
capac
health
system
must
address
million
peopl
global
current
infect
hookworm
caus
anemia
malnutrit
physic
development
delay
substanti
product
loss
phase
trial
human
hookworm
vaccin
found
safe
well
toler
immunogen
phase
trial
underway
use
control
human
hookworm
infect
model
parallel
market
research
financi
model
cost
benefit
conduct
develop
integr
busi
case
hookworm
vaccin
hepat
c
viru
hcv
preval
million
infect
global
caus
signific
mortal
liver
diseas
cancer
current
hepat
c
control
strategi
focu
improv
inject
safeti
diagnosi
access
treatment
lead
hcv
vaccin
approach
use
heterolog
primeboost
strategi
elicit
cellmedi
effector
immun
respons
candid
evalu
safeti
immunogen
phase
clinic
trial
data
expect
vaccin
potenti
transform
hepat
control
given
avail
effect
treatment
strong
valu
proposit
hcv
vaccin
must
still
establish
vaccin
frequent
drugresist
pathogen
prevent
infect
reduc
antimicrobi
use
promot
antibiot
stewardship
limit
emerg
spread
antimicrobi
resist
amr
ongo
activ
align
us
nation
action
plan
combat
antibioticresist
bacteria
expand
fund
opportun
vaccin
target
antimicrobialresist
pathogen
highlight
valu
vaccin
address
amr
present
gvirf
new
vaccin
target
pseudomona
staphylococcu
aureu
uropathogen
e
coli
develop
prevent
human
diseas
drive
antibiot
use
particip
observ
identifi
reach
appropri
target
popul
vaccin
may
challeng
especi
given
low
coverag
achiev
wellestablish
vaccin
influenza
progress
made
vaccin
combat
amr
gvirf
particip
caution
awar
accept
approach
remain
challeng
call
one
anoth
defin
commun
valu
vaccin
combat
amr
identifi
popul
would
benefit
consid
afford
access
lowand
middleincom
countri
everi
two
year
gvirf
take
stock
global
research
vaccin
immun
gvirf
highlight
power
vaccin
improv
health
enabl
progress
showcas
energi
creativ
immun
stakehold
worldwid
polio
near
erad
demonstr
power
wellcoordin
global
effort
pneumococc
rotaviru
vaccin
proven
valu
prevent
pneumonia
diarrhea
two
lead
caus
child
mortal
focu
improv
efficaci
costeffect
countri
india
thailand
make
stride
capac
develop
manufactur
regul
vaccin
progress
reflect
strong
particip
region
stakehold
first
time
gvirf
discuss
advanc
vaccin
deliveri
focus
health
system
innov
rather
deliveri
devic
reflect
endtoend
perspect
need
achiev
full
potenti
immun
signific
challeng
persist
howev
high
efficaci
hiv
tb
malaria
vaccin
remain
difficult
target
particip
call
greater
divers
idea
innov
pipelin
price
certain
vaccin
becom
unsustain
low
diminish
incent
develop
manufactur
enter
remain
market
even
new
vaccin
develop
launch
nearli
million
children
still
lack
access
vaccin
avail
mani
year
innov
urgent
need
improv
access
vaccin
primari
health
care
even
packag
intervent
continu
expand
gvirf
particip
highlight
two
factor
crucial
meet
need
focu
equiti
sustain
throughout
immun
ecosystem
enabl
polit
environ
priorit
health
immun
author
declar
known
compet
financi
interest
person
relationship
could
appear
influenc
work
report
paper
